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Abstract
Background The clinical and economic implications of an individualised intravenous immunoglobulin (IVIg) protocol for 
chronic inflammatory demyelinating polyneuropathy (CIDP) are unknown. Comparison with standard dosing regimens has 
not been performed.
Methods We retrospectively studied 47 IVIg-treated subjects with CIDP over 4 years with an individualised, outcome-
measured, dose-modifying protocol. We evaluated responder and remission rates, clinical improvement levels and dose 
requirements. We compared clinical benefits and costs with those reported with standard dosing at 1 g/kg every 3 weeks.
Results The IVIg-responder rate was 83% and the 4-year remission rate was 25.6%. Mean IVIg dose requirements were 
22.06 g/week (SD:15.29) in patients on ongoing therapy. Dose range was wide (5.83–80 g/week). Mean infusion frequency 
was every 4.34 weeks (SD:1.70) and infusion duration of 2.79 days (SD:1.15). Mean Overall Neuropathy Limitation Scale 
improvement was 2.54 (SD:1.89) and mean MRC sum score improvement of 12.23 (SD:7.17) in IVIg-responders. Mean 
modified-INCAT (Inflammatory Neuropathy Cause and Treatment) score improvement was similar (p = 0.47) and mean 
MRC sum score improvement greater (p < 0.001) in our cohort, compared to the IVIg-treated arm of the ICE Study. Mean 
drug costs were GBP 37,660/patient/year (€ 43,309) and mean infusion-related costs of GBP 17,115/patient/year (€ 19,682), 
totalling GBP 54,775/patient/year (€ 62,991). Compared to standard dosing using recorded weight, mean savings were of 
GBP 13,506/patient/year (€ 15,532). Compared to standard dosing using dosing weight, savings were of GBP 6,506/patient/
year (€ 7,482).
Conclusion Our results indicate that an individualised IVIg treatment protocol is clinically non-inferior and 10–25% more 
cost-effective than standard dosing regimens in CIDP.
Keywords Chronic inflammatory demyelinating polyneuropathy · Economic · Intravenous immunoglobulins · Outcome 
measures · Protocol
Introduction
Chronic inflammatory demyelinating polyneuropathy 
(CIDP) is the most common auto-immune neuropathy 
worldwide, with a prevalence of 3–5 per 100,000 in the 
United Kingdom [1, 2]. CIDP is treated with intravenous 
immunoglobulins (IVIg) as major first-line treatment.
Treatment regimens may in practice vary greatly in 
CIDP. Data on comparative levels of clinical benefit and 
costs are lacking, but are of great interest for clinical prac-
tice in view of IVIg cost and availability. Although effective 
non-protocolised, dose decrease to the minimal effective has 
long been described and advocated [3], the clinical gain and 
economic implications of a treatment protocol using close 
clinical monitoring of IVIg-treated patients to ascertain 
lowest possible effective dose and frequency requirements, 
refractoriness or remission, is not established in compari-
son to standard dosing at 1 g/kg every 3 weeks, as used in 
long-terms trials. True IVIg costs for CIDP are variable and 
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remain unclear as well as without demonstrated clinical jus-
tification, in the absence of clinical effectiveness data from 
economic analyses performed to date [4, 5].
We studied a cohort of patients with CIDP, followed-up 
at our institution and treated with IVIg as per an outcome-
measured treatment protocol, over a 4-year period. We ascer-
tained responder and remission rates. We determined clinical 
improvement levels, doses used, duration and frequency of 
IVIg infusions. We compared clinical benefits achieved with 
those previously described with standard dosing regimens. 
We also compared costs in our cohort with the hypothetical 
costs using standard dosing regimens.
Methods
We retrospectively reviewed electronic hospital records of 
patients with a diagnosis of CIDP attending the Inflamma-
tory Neuropathy Clinic, at Queen Elizabeth Hospital, Uni-
versity Hospitals Birmingham, UK. Patients were selected 
on the basis of (1) meeting European Federation of Neu-
rological Societies/Peripheral Nerve Society (EFNS/PNS) 
diagnostic criteria for “definite” or “probable” CIDP [6], 
and (2) having received IVIg treatment between July 2014 
and June 2018.
IVIg-response is primarily defined in our clinical prac-
tice, by a ≥ 1-point improvement of the Overall Neuropathy 
Limitation Scale (ONLS) [7], excluding a grade 1 to grade 
0 amelioration of the upper limb component, as not func-
tionally meaningful. In those not meeting this requirement, 
patients are considered as responders if they demonstrate 
an improvement of ≥ 4 raw points (out of 48) of the inflam-
matory Rasch-built Overall Disability Scale (I-RODS) [8], 
and/or a ≥ 5 kg improvement of Jamar grip strength of the 
dominant or clinically more affected hand [9, 10]. Addition-
ally, we also consider improvements of lesser amplitudes 
of the I-RODS and Jamar grip as consistent with an IVIg-
response, if both are concurrently present, with, in addition, 
an accompanying Medical Research Council (MRC) Sum 
Score (MRCSS) improvement by ≥ 2 points. The MRCSS 
(out of 80) is determined by adding individual MRC scores 
from eight muscle groups bilaterally, including shoulder 
abductors, elbow flexors, wrist extensors, finger abductors, 
hip flexors, knee flexors, ankle dorsiflexors and extensor 
hallucis.
IVIg dose changes are implemented using the local 
version of a jointly previously proposed algorithm, pub-
lished by others and ourselves [11]. Our protocol (Fig. 1) 
involves treatment initiation at 2 g/kg, using dosing weight 
(DW). Two courses separated by 4 weeks are attempted 
to determine IVIg response or refractoriness. In respond-
ers, further courses at the same dose of 2 g/kg of DW are 
administered at 4-week intervals, if and as necessary, until 
complete or near-complete improvement or plateauing of 
function, defined by absence of further functional amelio-
ration after two successive courses. Courses are adminis-
tered more frequently after any of the initial courses at 2 g/
kg of DW, if deterioration occurs before 4 weeks. Subse-
quent regular reassessments are conducted with suspension 
of IVIg treatment to determine dosing interval. Next, with 
treatment administered at the established dosing interval, 
and after one further stabilising course at 2 g/kg of DW, 
weight-independent, gradual, step-wise dose reductions of 
15–25% at each review (every two to three courses), are 
performed until the lowest effective dose is reached, or 
weaning achieved. Eventual 15–25% dose re-increase is 
performed if and when deterioration occurs at a later stage 
and stabilisation attempted at that dose. Decline is defined 
as per above-mentioned cut-offs for ONLS, I-RODS and 
Jamar grip strength. If unsuccessful on the first occasion 
following progressive dose reductions, wean is similarly 
re-attempted on a yearly basis.
For each patient, we identified demographics, diagnostic 
criteria category fulfilment, CIDP subtype, relevant associ-
ated conditions and relevant associated treatments. In each 
case, we ascertained the initial IVIg dose administered as per 
patients’ DW, calculated as per the previously published for-
mula adopted by the 2011 Clinical Guidelines for Immuno-
globulin Use, Department of Health, UK: (DW = Ideal Body 
Weight + [0.4 × {recorded weight − Ideal Body Weight}, 
except if recorded weight ≤ Ideal Body Weight, in which 
case DW = recorded weight) [12]. As, in our experience, 
recorded weight remains frequently used instead of DW in 
clinical practice at many prescribing institutions in the UK 
and elsewhere, and as long-term IVIg trials for CIDP do not 
make specific mention of this issue, theoretical initial IVIg 
drug costs were also calculated using recorded weight at 
treatment initiation.
Responder rate, remission rate over the study period, IVIg 
doses, infusion durations and frequencies were obtained 
from records, as documented at last follow-up. Pre- and 
post-treatment disability scores were retrieved. IVIg drug 
costs were calculated using the mean current cost per gram 
(as of July 2018), of the three most used brands in our unit. 
Hospital infusion-related non-drug costs were calculated 
considering current cost of a day on our Day Case Unit, 
although some patients were treated in their local district 
hospital but monitored in our clinic. As a result, total IVIg-
related costs per patient on on-going treatment, were deter-
mined. Disability score improvements were compared with 
those achieved in previous long-term IVIg trials for CIDP 
using standard dosing regimens [13, 14]. Costs were simi-
larly compared with those of these regimens using current 
costs at our institution [13, 14].
Statistical analysis was performed using SPSS 25.0 soft-
ware. Comparisons of proportions were done using Fisher 
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Exact Tests, and comparison of means by t tests. Signifi-
cance was set at p < 0.05.
This study was an approved and registered retrospective 
Clinical Audit by our institutional review body at University 
Hospitals Birmingham, UK (Registration number: CARMS 
14164, March 2018).
Results
Amongst subjects with a diagnosis of “definite” or “prob-
able” CIDP as per EFNS/PNS diagnostic criteria [6] attend-
ing our Inflammatory Neuropathy Clinic between July 2014 
and June 2018, 47 had been treated with IVIg. Thirty-nine 
subjects (83%) had responded as determined by the outcome 
measures as defined above.
The group of responders consisted of ten women and 
29 men. Mean age was 58.36 years (SD: 15.06). Thirty-six 
patients (92.3%) fulfilled clinical and electrophysiological 
diagnostic criteria for “definite CIDP” as per the EFNS/
PNS Guidelines [5]. Three (7.7%) met criteria for “prob-
able CIDP”. The majority (32; 82.1%) had typical CIDP as 
defined by the EFNS/PNS Guidelines [5], 6 (15.4%) had 
Lewis-Sumner syndrome and one (2.6%) had pure motor 
CIDP. Five patients (12.8%) had associated diabetes, and 6 
patients (15.4%) had an associated monoclonal gammopathy 
of uncertain significance (MGUS). Three of the 39 respond-
ers were on concurrent immunosuppressive treatment with 
methotrexate, two for concurrent rheumatological indica-
tions, and one for CIDP, initiated outside our institution. Uti-
lised outcome measures used included MRCSS and ONLS 
in all 39 subjects, I-RODS in 26/39 (66.7%), and Jamar grip 
dynamometry in 20/39 (51.3%).
Main findings relating to mean clinical amelioration with 
IVIg are summarized in Table 1. Mean improvements in 
the 39 responders were of 12.23 (SD: 7.17) for the MRCSS 
and 2.54 (SD: 1.89) for the ONLS. All 39 IVIg respond-
ers improved by ≥ 2 points on the MRCSS. Thirty-six 
of 39 responders (92.3%) improved on the ONLS by ≥ 1 
point. Nineteen of 26 (73.1%) improved by ≥ 4 points on 
Abbreviaons: CIDP: chronic inflammatory demyelinang polyneuropathy; DW: Dosing weight; IVIg: 
intravenous immunoglobulins; 
Iniaon IVIg 2 g/kg of DW
Further courses of 2g/kg DW every 4 weeks, if needed, unl complete/near complete improvement or plateauing
4 weeks
2nd course IVIg 2 g/kg DWIf deterioraon before 4 weeks
weeks
IVIg RESPONSIVE IVIg REFRACTORY
Suspend IVIg treatment to determine dosing interval 
interval
Administer one stabilising course at 2 g/kg of DW on deterioraon
Re-treat at the established dosing interval
Reduce IVIg dose by 15-25% at each review (every 2-3 courses) unl lowest effecve dose is reached
Remission and wean off IVIg Late Deterioraon: Re-stabilised at higher dose (15-25%)
Reaempt wean off IVIg yearly
Fig. 1  IVIg outcome-measured dose-modifying protocol for CIDP. Abbreviations: CIDP chronic inflammatory demyelinating polyneuropathy, 
DW dosing weight, IVIg intravenous immunoglobulins
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the I-RODS. Fourteen of 20 (70%) improved by ≥ 5 kg on 
Jamar grip dynamometry. Thus, 38/39 (97.4%) of responders 
improved as per defined cut-offs on at least one scale. One of 
the 39 responders (2.6%), improved to levels below cut-offs 
for both I-RODS and Jamar grip, with additional MRCSS 
amelioration.
Comparative statistical analysis of clinical amelioration 
was possible with one of the two previous trials with stand-
ard dosing [13] but not the other [14], and for the modified-
INCAT (Inflammatory Neuropathy Cause and Treatment) 
and MRCSS scales only for which complete data were 
available for all participants. For the purposes of this part 
of the analysis, we included all 47 patients meeting crite-
ria for “definite” or “probable” CIDP, including the eight 
IVIg-non-responders. This was done because the results 
from the previous trial included both IVIg-responders and 
non-responders [13]. The corresponding modified-INCAT 
scores and improvement levels were directly obtained from 
the ONLS scores for each one of our 47 treated subjects [7]. 
Modified-INCAT improvement levels were similar to those 
of the IVIg arm of the ICE Study [13], [mean: 1.45 (SD: 
1.73) vs. mean: 1.2 (SD: 1.5); p = 0.47]. MRCSS improve-
ment was greater in our 47 patients as compared to the IVIg 
arm of the ICE Study [13] [mean: 10.15 (SD: 8.0) vs. mean: 
4.4 (SD: 6.5); p < 0.001].
Initial courses had been administered in our patients using 
DW, over 5 days, although 12 patients (30.8%) had received 
higher doses based on recorded weight at first treatment 
outside our institution. Mean initial IVIg dose at 2 g/kg, 
using DW, was 152.8 g per course. Mean initial theoretical 
IVIg dose, using recorded weight at 2 g/kg, was 177.4 g per 
course. This implied administration of a mean extra 24.6 g/
patient/course in initial disease stages as per our treatment 
protocol.
Mean final IVIg infusion duration in the 29 patients 
remaining on long-term treatment was 2.79  days (SD: 
1.15) and mean final IVIg infusion frequency was every 
4.34 weeks (SD: 1.70). Mean final IVIg dose infused was 
of 22.06 g/patient/week (SD: 15.29). However, 37.9% of 
patients required ≤ 15 g/week, 62.1% required ≤ 20 g/week 
and 75.9% required ≤ 25 g/week. On the other hand, 24.1% 
required ≥ 30 g/week and 10.3% required ≥ 35 g/week. Thus, 
a significantly greater proportion of patients on on-going 
treatment had low IVIg dose requirements of ≤ 15 g/week, 
compared to high dose requirements of ≥ 35 g/week (11/29 
vs. 3/29; p = 0.03).
Our main results for doses and costs as well as the hypo-
thetical values with standard dosing, are summarised in 
Table 2. The current cost of IVIg was estimated at GBP 
32.83/g (€ 37.75), this representing the average price of the 
three main brands used at our institution (July 2018). The 
Table 1  Mean clinical improvement achieved on different disability 
outcome measures with treatment in 39 IVIg-responders with CIDP 
on long-term therapy over a 4-year period using an outcome-meas-
ured protocol
MRCSS
Mean (SD)
ONLS
Mean (SD)
39 IVIg responders 12.23 (7.17) 2.54 (1.89)
29 long-term IVIg-dependent 12.54 (5.46) 2.32 (2.00)
10 patients in remission 10.80 (6.63) 3.20 (1.40)
Table 2  Mean costs of IVIg treatment in 29 patients with CIDP on long-term treatment: real costs using an outcome-measured treatment proto-
col vs. hypothetical costs using standard dosing at 1 g/kg every 3 weeks using (1) dosing weight and (2) recorded weight
Mean 
Weekly 
IVIg Dose 
Used
(g/week)
Mean 
Yearly IVIg 
Dose Used
(g/year)
Mean 
Infusion 
Fre-
quency
(inter-
val in 
weeks)
Mean 
Infusion 
Duration
(days)
Mean Yearly 
IVIg Drug 
Costs 
GBP/patient
(€)
Mean Yearly IVIg infu-
sion related non-drug 
costs 
GBP/patient
(€)
Mean Total Yearly 
IVIg related Costs 
GBP/patient
(€)
Real IVIg consumption 
and costs incurred with 
Protocol and outcome 
measures used
22.06 1149 4.34 2.79 37,660
(€ 43,309)
17,115
(€ 19,682)
54,775
(€ 62,991)
Consumption and costs 
with hypothetical 
standard dosing at 1 g/
kg/ 3 weeks using dos-
ing weight
25.50 1326 3 2 43,532
(€ 50,062)
17,749
(€ 20,411)
61,281
(€ 70,473)
Consumption and costs 
with hypothetical 
standard dosing at 1 g/
kg/ 3 weeks using 
recorded weight
29.60 1539 3 2 50,532
(€ 58,119)
17,749
(€ 20,411)
68,281
(€ 78,523)
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mean IVIg drug cost was, therefore, of GBP 37,660/patient/
year (€ 43,309) for those on on-going treatment. In view of 
the mean infusion frequency and duration and daily cost 
on our Day Case Unit (GBP 512; € 589), hospital infusion-
related non-drug costs amounted to a mean of GBP 17,115/
patient/year (€ 19,682). Total IVIg costs consequently 
amounted to a mean of GBP 54,775/patient/year (€ 62,991) 
for patients on on-going IVIg, with IVIg drug costs repre-
senting 68.8% of total IVIg-related costs.
Ten of the 39 patients (25.6%), were successfully taken 
off IVIg therapy during the study period as a result of dis-
ease remission. Age (p = 0.75) and gender (p = 1) distribu-
tion were similar in these ten patients as in the 29 remaining 
on treatment.
Details relating to cost savings achieved with our pro-
tocol are provided in Table 3. Applying standard dosing 
treatment regimens of 1 g/kg administered every 3 weeks 
using DW, mean total IVIg costs were higher than the actual 
expenses in our cohort, by GBP 6,506/patient/year (€ 7,482), 
i.e., 11.9%. Applying standard dosing with recorded weight 
instead of DW, the mean total overspend, would have been 
of GBP 13,506/patient/year (€ 15,532), i.e., 24.7%.
Discussion
The clinical and economic aspects of IVIg treatment for 
CIDP are complex and have not been studied specifically. 
Although central, the questions surrounding diagnostic accu-
racy, responder rate, minimum effective dose and frequency 
requirements, weight-based dosing, use of disability scales, 
implementation of functional score cut-off levels and remis-
sion rate, have not been included in analyses performed to 
date.
We here investigated the objective functional gain and 
costs of IVIg treatment in a UK cohort of patients with 
CIDP attending our unit, all fulfilling EFNS/PNS criteria 
for a “definite” or “probable” diagnosis, monitored using 
validated disability scales with defined cut-offs for clini-
cal benefit and implementing a dose-altering protocol. The 
resulting analysis is, to our knowledge, the first to consider 
all these points and, therefore, provides accurate results 
directly in relation to quantified clinical benefit and real-life 
costs of IVIg-treated CIDP. Clinical and economic data were 
compared with those of existing standard dosing regimens. 
To our knowledge, this is the first study to compare these 
aspects with different IVIg treatment strategies for CIDP.
We found that mean IVIg drug costs amounted to GBP 
37,660/patient/year (€ 43,309), for subjects on on-going 
treatment. These appear higher than previously reported in 
the UK, which were of GBP 34,215 (€ 39,347) for total IVIg 
costs [4]. Considering identical proportions to our findings 
of drug and non-drug costs for that study conclude to a fig-
ure of GBP 23,523 (€ 27,051) for IVIg drug costs only. As 
that analysis described a mean IVIg dose per course of 135 g 
and quoted estimated costs of GBP 33/g (€ 37.95), this indi-
cates that patients received a mean of 713 g/ year (13.71 g/
week) and a mean of 5.28 courses yearly. This equates to 
a mean infusion frequency of every 9.85 weeks, i.e., over 
twice less frequently than what is reported as average needs 
Table 3  Mean savings achieved during IVIg treatment in 29 patients 
with CIDP on long-term treatment using an outcome-measured treat-
ment protocol with cut-offs defining response vs. hypothetical costs 
using standard dosing at 1 g/kg every 3 weeks using dosing weight 
and recorded weight
Mean IVIg 
dose saved in g/ 
patient/week
Mean IVIg 
dose saved in g/ 
patient/year
Rounded Num-
ber of avoided 
infusions ses-
sions/year
Rounded Num-
ber of avoided 
Infusion days /
year
Mean IVIg 
Drug Costs 
saved/patient/
year 
GBP
(€)
Mean IVIg 
non-drug Costs 
saved/ patient /
year 
GBP
(€)
Mean Total IVIg 
Costs saved/
patient/year 
GBP
(€)
Savings 
achieved 
compared to 
Standard Dos-
ing at 1 g/kg/3 
weeks using 
dosing weight
3.44 179 6 1 5872
(€ 6,753)
634
(€ 729)
6506
(€ 7,482)
Savings 
achieved 
compared 
to Standard 
Dosing of 1 g/
kg/ 3 weeks 
using recorded 
weight
7.54 392 6 1 12,872
(€ 14,803)
634
(€ 729)
13,506
(€ 15,532)
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in relapsing CIDP, i.e., about every 4 weeks, as indicated 
from different cohorts [11, 15, 16]. It is consequently possi-
ble that, in this previously studied cohort, for which clinical 
amelioration levels were not described, undertreatment may 
have occurred, explaining lower costs.
The mean IVIg dose administered in our long-term 
patients with CIDP was of 22.06 g/week. This compares 
cost-wise favourably to the dose of 1 g/kg/3 weeks, found 
effective in stabilising the condition in the medium and long-
term in recent trials [13, 14]. It is noteworthy that marked 
inter-subject dose requirement variations were observed, 
as we and others had previously reported [3, 15, 16]. The 
majority (62.1%) of our patients had requirements of ≤ 20 g/
week. Concurrently, our protocol allowed at higher dose and 
cost, stabilising nearly a quarter of long-term IVIg-respond-
ing subjects with requirements of ≥ 30 g/week, at optimal 
levels of neurological function. Very high IVIg needs are 
described in a minority of patients with CIDP [17] and find-
ing and implementing the right dose in these subjects may be 
challenging, particularly in view of existing guidelines and 
monitoring by local hospital-based regulating bodies. This 
is, however, imperative to ensure optimum patient benefit 
and likely to otherwise also favourably impact on primary 
and social care costs, which were not considered here.
From the clinical perspective, the modified-INCAT score 
improvement in our cohort was similar to that reported in the 
ICE Study, considering a similar-sized IVIg-treated group, 
using a standard dosing regimen [13]. The MRCSS improve-
ment was otherwise significantly greater in our patients. 
These findings may partly relate to a greater proportion of 
our patients being severely weak at baseline and improv-
ing to greater levels of muscle strength, although to similar 
levels of function. The results indicate non-inferiority of the 
clinical benefit achieved with our protocol in comparison to 
standard dosing at 1 g/kg/3 weeks.
We and others have previously described the absence of 
correlation of recorded weight with IVIg dose requirements 
in CIDP [3, 15, 16]. The current analysis is, however, the 
first, to our knowledge, to demonstrate the clinical equiva-
lence of DW to recorded weight in the initial stages of CIDP 
treatment. This is important as the use of recorded weight 
remains widespread both in clinical practice and research. 
Use of DW allowed mean savings of GBP 808/patient/course 
(€ 929) in early treatment stages as per our protocol. Further-
more, administration of lower IVIg doses may be protective 
against the risk of thromboembolic complications [18].
Our IVIg-responder rate, whether considering the above-
described definition used in our clinical practice (39/47; 
83%), or modified-INCAT score amelioration only (33/47; 
70.2%), as well as our remission rate (25.6%), were simi-
lar to those previously reported [14, 19, 20]. This suggests 
that our cohort is comparable to previously described CIDP 
populations and that our findings have wide applicability.
Our analysis is limited by its retrospective design and 
consideration of treatment costs only within the hospital 
environment. The comparative analysis with historical con-
trols from the ICE Study is a drawback although use of a 
contemporary control group was not possible in view of the 
design of this cohort study of clinical practice within our 
unit. The final documented dose analysis we used for cost 
calculations is subject to possible future change in treatment 
requirements in some patients. Nevertheless, the extended 
retrospective review over a 4-year period, offers a global and 
protracted view of IVIg requirements in a CIDP cohort. It is 
finally possible that the IVIg doses used were high in a rela-
tively large number of our patients. A proportion of subjects 
were referred to our tertiary centre as a result of refractori-
ness and high-dose and/or high-frequency IVIg therapy is 
known to be effective in some patients in this setting [21].
Subcutaneous immunoglobulin (SCIg) therapy may rep-
resent the future of CIDP treatment [22]. However, drug 
costs will remain a predominant question, representing 
in our analysis, nearly 70% of immunoglobulin treatment 
costs. Therefore, similarly protocolised SCIg treatment may 
require consideration in comparison to standard dosing in 
future.
In conclusion, total IVIg costs are for CIDP, without 
compromising on clinical benefit, 10–25% lower with an 
individualised treatment protocol, than with standard dos-
ing regimens. Our cost variation estimates, using DW and 
recorded weight from a real patient cohort, indicate that 
use of DW should be implemented at treatment initiation 
to avoid unnecessary excessive IVIg expenditure in the first 
treatment stages. More importantly for the long-term, use 
of a subsequently weight-independent, outcome-measured, 
dose-modifying protocol with defined cut-offs for clinical 
benefit, appears optimal for management of both clinical 
and economic aspects of IVIg-treated patients with CIDP.
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